Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Alnylam Pharmaceuticals, Inc.

NASDAQ: ALNY · Life Sciences · 6 alerts · CIK 1178670

Share price
$159.73Close, Nov 16
Market cap
$21.4B
Shares outstanding
133.94MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Alnylam Pharmaceuticals, Inc. filings on SEC EDGAR ↗

4:06 PM ET Form 4
Insider Buying

Alnylam Pharmaceuticals Insider Charles Elliott Sigal Buys $244K of Stock

Charles Elliott Sigal bought 1,600 shares of Alnylam Pharmaceuticals, Inc. at $152.25 a share, worth $244K in total on Nov 10, 2026. Shares held after the trade: 3,600 (+80.0%).

Value
$244K
Shares
1,600
Price
$152.25
Holding change
+80.0%
Trade date
Nov 10, 2026
4:02 PM ET Form 4
Insider Buying

Alnylam Pharmaceuticals Insider Amy W. Schulman Buys $300K of Stock

Amy W. Schulman bought 1,910 shares of Alnylam Pharmaceuticals, Inc. at $156.82 a share, worth $300K in total on Nov 9, 2026. Shares held after the trade: 25,959 (+7.9%).

Value
$300K
Shares
1,910
Price
$156.82
Holding change
+7.9%
Trade date
Nov 9, 2026
7:37 AM ET 8-K
Stock Buyback

Alnylam Pharmaceuticals Announces $1B Stock Buyback

Alnylam Pharmaceuticals announced that its Board of Directors authorized a new $1.0 billion share repurchase program. The company expects to repurchase approximately $500 million of its common stock by the end of 2026, with the remaining balance planned for 2027. Additionally, the company disclosed that Tolga Tanguler will depart from his role as Executive Vice President and Chief Commercialization Officer in December 2026.

Value
$1B
8:16 AM ET 8-K
Financial Results

Alnylam Pharmaceuticals Financial Results

Alnylam Pharmaceuticals reported Q3 2026 global net product revenues of $1,292 million, representing 52% year-over-year growth. The performance was driven by its TTR franchise, which grew 59% to $1,150 million, and the company reaffirmed its full-year 2026 financial guidance.

Term
Q3 2026

“Our third quarter results reflect the continued growth of our TTR franchise and advancement of key programs with the potential for transformative patient impact. As we continue through the final months of the year and plan for 2027, we remain laser focused on leveraging our commercial investments to expand the prescriber base, support access, and bring AMVUTTRA to more patients with ATTR amyloidosis.”

Yvonne Greenstreet, M.D., Chief Executive Officer of Alnylam
4:12 PM ET Form 4
Insider Selling

Alnylam Pharmaceuticals EVP, CLO and Secretary Bryan Supran Sells $399K of Stock

Bryan Supran, EVP, CLO and Secretary, sold 1,758 shares of Alnylam Pharmaceuticals, Inc. at $226.88 a share, worth $399K in total on Oct 2, 2026. Shares held after the trade: 12,807 (-12.1%).

Value
$399K
Shares
1,758
Price
$226.88
Role
EVP, CLO and Secretary
Holding change
-12.1%
Trade date
Oct 2, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.